Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. - Wikidata - awgldk - TriplyDB

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

http://www.wikidata.org/entity/Q44506875

about

Polyphosphate and omptins: novel bacterial procoagulant agents Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins Recently published papers: curing, caring and follow-up Bench-to-bedside review: acute respiratory distress syndrome - how neutrophils migrate into the lung.Brazilian Sepsis Epidemiological Study (BASES study)Coagulation in sepsis: all bugs bite equally Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis The coagulopathy of acute sepsis Host innate immune responses to sepsis Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective Sepsis and ARDS: The Dark Side of Histones Platelets and coagulation in infection The electrocardiogram for sepsis: how close are we?Microvesicle-associated tissue factor and Trousseau's syndrome Sepsis: in search of cure.Delta inflation: a bias in the design of randomized controlled trials in critical care medicine.A recombinant fragment of von Willebrand factor reduces fibrin-rich microthrombi formation in mice with endotoxemia Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature.Beyond heparin and warfarin: the new generation of anticoagulants.New parenteral anticoagulants in development.Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.Cellular sources of tissue factor in endotoxemia and sepsis.The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation Myeloid-derived suppressor cells in sepsis Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia.High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.Protocolized Care for Early Septic Shock (ProCESS) statistical analysis plan.Activated protein C action in inflammation Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival.Inflammation and thrombosis in cardiovascular disease.A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection.Curcumin modulates leukocyte and platelet adhesion in murine sepsis.A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome.Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria.The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients

P2860

Q24629548-40BFAF67-5B9B-45AB-8031-24828F73F98D Q24646845-53B072A2-EA3E-4F9A-9198-FA0BB88D81AC Q24658383-16AA2416-1350-450E-988C-787B6D05A87A Q24796218-C530C0E3-F9F7-4CF2-AD34-C523D29C9270 Q24800620-288C08A9-419F-4754-920C-A4599790116D Q24801014-7CA267D6-8CF6-4928-A321-6DD0E6D14D26 Q24805503-8DD66270-9156-43F5-8B29-BE28019471D8 Q24810495-987F908E-8AEB-440F-B61F-D57C9AA39BF0 Q25255548-A09D4015-533D-4B66-8F2C-B3B6C727E5F9 Q26753103-D4A3F597-7B30-4EF3-8BC9-6F329A49CDF5 Q26783097-80ADFB4F-233F-42B0-B074-6CFBC678F792 Q26826950-A0D011C2-9B3D-4DC1-BB29-8CA3AEB7C883 Q26864635-76B9A441-9E11-4AEC-958A-C49FE5E1C9EF Q26995417-9B64A472-F30B-474D-B876-FD5008F04F63 Q27027282-8963B314-C832-4CF1-B38B-33A0B87540CE Q28079908-E645049B-4E3F-4772-B508-FD1E8F55E1D3 Q28217952-32879E52-1BCA-4807-8E10-C149F20B098F Q29026182-45E552AB-88EA-426B-90AC-9335FCEC89D0 Q30251753-250E0DC2-5A3B-4C9F-8ACA-AABF087C6130 Q30435820-11348540-2FBD-4CB4-8A0E-3AE9079DF9E9 Q30836660-A3A160AB-029E-41A4-B785-1AC1F418D987 Q33288475-C2B9BCAC-8229-45D6-8B2D-01C674AB7038 Q33374258-78DAD2AF-1190-423F-ACCB-45E74F48421F Q33392647-AE42B785-2865-43A1-AB5E-E5A41BBB2B0A Q33426245-AC2C657C-82F1-4EEC-B6B3-3C90DA679EE0 Q33729477-F7E44FA7-095F-4C64-A186-2070B6B22919 Q33751764-13CF1011-6E55-4CF0-AF77-846B217877CE Q33786718-AE65148E-35A6-4CA4-A656-BA9B29F45731 Q33814903-025EED8B-A623-4062-8CD4-286A183D3AB4 Q33815424-8D8DF0F7-AB67-490E-8E34-8F22A62C5EAD Q33836853-EEF644B8-51D3-456F-9408-D6F2469719B9 Q33844701-F415FAF3-7627-4E42-B8F2-838F35BE803B Q33846825-30B7BF9F-53C1-43A9-AF97-3E9545E999F1 Q33853372-9EE64907-7795-472F-BEA7-E3A2BC16CED7 Q33864069-AC96FE44-B8BE-48A6-B72F-8537AA7C728E Q33927961-68820858-12D8-4A67-9C91-DF1058A93E1A Q34058712-F56A583F-DA84-4D8C-9F9E-293C34836540 Q34160584-0B4200BC-2AB3-44C6-9D28-0BC1015AF23E Q34220502-FE9D2086-E2AD-4D8E-A5F9-B3E6902BE231 Q34257657-6A85E15F-68B2-4941-BBD8-8179A70CDFE0

P2860

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

http://www.wikidata.org/entity/Q44506875

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Efficacy and safety of tifacog ...... a randomized controlled trial.

@en

Efficacy and safety of tifacogin

@nl

type

label

Efficacy and safety of tifacog ...... a randomized controlled trial.

@en

Efficacy and safety of tifacogin

@nl

prefLabel

Efficacy and safety of tifacog ...... a randomized controlled trial.

@en

Efficacy and safety of tifacogin

@nl

P1433

Q44506875-D5DCCFC7-EB9F-4752-AF7E-EAC8E5AA0FA8

P1476

Q44506875-C68CE24E-EF5A-4DC3-89E7-BCCD4C01F2F1

P2093

Q44506875-04C56AB0-2BD7-4A45-8CDA-86F08C5B1DA8

Q44506875-0CE2DE60-EDDF-46A6-9FB6-62373D7A535E

Q44506875-12822682-2B5C-4C0A-B3FB-A9AC5F1BA643

Q44506875-220789A5-8432-4CAB-8FFC-5A339B95145F

Q44506875-24EEF5E7-8D1F-4A58-8AB6-C133953BD006

Q44506875-3031BF45-225E-4DAC-AE9D-8C105D4628AF

Q44506875-3A1AA743-CE5B-4F9A-890A-40A6D07D0CE8

Q44506875-4D45B34C-DD52-4BDE-B99F-28D6487EC6D2

Q44506875-575C8E47-1CEB-478B-B886-D656D0DF16F6

Q44506875-5EEB4D35-CEF3-444C-AD0E-437C91D1AD4E

P304

Q44506875-CBEF6E0B-1DBA-4AF5-BF78-9E4504F89CDC

P31

Q44506875-3C2EEFE0-C305-4570-945F-61804CE011D0

P356

Q44506875-8B8C120E-166D-4AAA-B844-61298C9C049B

P407

Q44506875-17B37E0E-5C28-4AAD-8FB9-2716073C59E4

P433

Q44506875-E7AD3A37-3656-429B-9350-5E5791BD8E9F

P478

Q44506875-00C88867-BD45-443E-8AF8-ED7CA194D25D

P50

Q44506875-B4CE75B6-0B61-4170-A2A1-66BF0A71EAA9

P577

Q44506875-1ABCDD47-284C-44A7-8180-245A9A6462E9

P5875

Q44506875-FE026CF3-9002-484B-A3BA-73E36837597C

P698

Q44506875-CA442E71-CC80-47EF-BB77-9D7A399A49F3

P921

Q44506875-20A09442-E4BC-45E9-A691-ED1F2BAE361A

P356

P1433

Journal of the American Medical Association

P1476

Efficacy and safety of tifacog ...... a randomized controlled trial.

@en

P2093

Abla A Creasey

http://www.w3.org/2001/XMLSchema#string

Allan Seibert

http://www.w3.org/2001/XMLSchema#string

Angel López Rodriguez

http://www.w3.org/2001/XMLSchema#string

Antonio Artigas

http://www.w3.org/2001/XMLSchema#string

Bruce Light

http://www.w3.org/2001/XMLSchema#string

Cathy De Deyne

http://www.w3.org/2001/XMLSchema#string

Christian Zwingelstein

http://www.w3.org/2001/XMLSchema#string

Christopher Doig

http://www.w3.org/2001/XMLSchema#string

Claus Peckelsen

http://www.w3.org/2001/XMLSchema#string

Edward Abraham

http://www.w3.org/2001/XMLSchema#string

P304

238-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.290.2.238

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

290

http://www.w3.org/2001/XMLSchema#string

P50

Charles L Sprung

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10670653

http://www.w3.org/2001/XMLSchema#string

P698

12851279

http://www.w3.org/2001/XMLSchema#string

P921